61 completed, 12 unknown, 5 recruiting, 3 terminated. 85 Phase 1, 29 Phase 2.
Follow Attention Deficit and Disruptive Behavior Disorders: new trials by email Literature Review of Attention Deficit and Disruptive Behavior Disorders trials Research Report on Attention Deficit and Disruptive Behavior Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Clinical Study of Non-invasive 40-Hz Audiovisual Stimulation Guided by Gamma EEG Monitoring for Promoting Perioperative Brain Function Recovery in Children 40-Hz non-invasive synchronized audiovisual stimulation - ADHD - Attention Deficit Disorder With Hyperactivity | Phase 1 | Not yet recruiting | General Hospital of Ningxia Medical University | 80 | 2026-09-15 | 2026-07-22 |
| Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD) Experimental: Full-spectrum CBG oil 30 mg/mL, Placebo oil (MCT oil) - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 60 | 2026-05-01 | 2026-05-18 |
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body Centanafadine, Methylphenidate, Lisdexamfetamine - ADHD | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 40 | 2026-02-05 | 2026-05-05 |
| Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease Extended-Release Methylphenidate - Sickle Cell Disease, Executive Dysfunction | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 72 | 2025-11-25 | 2026-09-09 |
| A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder BI 3031185, Placebo - Borderline Personality Disorder, Attention Deficit Hyperactivity Disorder | Phase 1 | Completed | Boehringer Ingelheim | 78 | 2025-08-12 | 2026-08-10 |
| To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions. Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard) - Attention Deficit/Hyperactivity Disorder (ADHD) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 48 | 2025-05-26 | 2025-08-01 |
| Pathways 2 Success L2B, L2B + App, skills for success - Conduct Disorder, Oppositional Defiant Disorder | Phase 1 / Phase 2 | Recruiting | University of Minnesota | 120 | 2025-03-12 | 2026-04-13 |
| Dual-target iTBS for Youth With ADHD TMS - ADHD | Phase 1 / Phase 2 | Recruiting | Shanghai Mental Health Center | 15 | 2025-01-01 | 2025-07-24 |
| A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels CTN XR (TBM), CTN SR, CTN XR (Clin) - Attention Deficit Disorder With Hyperactivity | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 174 | 2024-08-29 | 2025-12-11 |
| Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial Non-adaptive Floreo VR control, Floreo Virtual Reality application - Attention Deficit Hyperactivity Disorder | Phase 1 / Phase 2 | Recruiting | National Institute of Mental Health (NIMH) | 219 | 2024-03-15 | 2026-10-08 |
| Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD Virtual Reality, Comparative Control - Conduct Disorder, Conduct Disorders in Children | Phase 1 | Completed | Virginia Commonwealth University | 220 | 2024-02-16 | 2026-06-17 |
| Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects Centanafadine - Healthy Adult Participants | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 44 | 2023-03-08 | 2026-03-23 |
| Biomarkers of ADHD Treatment Response Concerta, Adderall-XR - ADHD | Phase 1 | Completed | Boston Children's Hospital | 16 | 2023-02-17 | 2024-12-18 |
| Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities Methylphenidate Oral Solution - Intellectual Disability, Fragile X Syndrome | Phase 1 | Enrolling by invitation | University of California, Davis | 68 | 2023-02-01 | 2025-12-15 |
| A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder Centanafadine - Attention-deficit Hyperactivity Disorder | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 50 | 2021-03-09 | 2023-07-13 |
| Technology-Enhanced Executive Functioning Intervention for ADHD Homework Organization and Planning Skills (HOPS) Intervention, Digital Health Application (Online Platform) for Encouraging Skills Practice - ADHD, Attention Deficit Hyperactivity Disorder | Phase 1 | Unknown | Children's National Research Institute | 60 | 2021-02-03 | 2023-02-21 |
| Task-Based Grounding Program Task-Based Grounding, Connected Care (Enhanced Treatment as usual) - Aggressive, Defiant Disorder, Oppositional | Phase 1 | Completed | Dartmouth-Hitchcock Medical Center | 28 | 2020-12-03 | 2021-11-08 |
| Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo - ADHD, Narcolepsy | Phase 1 | Completed | Vallon Pharmaceuticals, Inc. | 55 | 2020-10-05 | 2021-12-29 |
| Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning. Calcitriol, Placebo - ADHD | Phase 1 | Terminated | Yale University | 3 | 2020-08-05 | 2024-02-07 |
Showing 20 of 85. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (78) · Conduct Disorder (7) · Depression (4) · Oppositional Defiant Disorder (4) · Dyslexia (2) · Narcolepsy (2) · Smoking (2) · Aggression (1) · Amphetamine-Related Disorders (1) · Anemia, Sickle Cell (1) · Asperger Syndrome (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Binge-Eating Disorder (1)
Neurodevelopmental Disorders (85) · Mental Disorders (84) · Behavior (11) · Nervous System Diseases (11) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Behavioral Symptoms (6) · Neurobehavioral Manifestations (5) · Chemically-Induced Disorders (4) · Child Development Disorders, Pervasive (3) · Communication Disorders (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Dyssomnias (3)
Methylphenidate (11) · Lisdexamfetamine Dimesylate (6) · Dextroamphetamine (4) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (3) · Atomoxetine Hydrochloride (3) · Calcitriol (2) · bavisant (2) · 3-(2,4-dimethoxybenzylidene)anabaseine (1) · 3-(5-chloro-2-furoyl)-3,7-diazabicyclo(3.3.0)octane (1) · 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine (1) · 5,10-dihydro-5-methylphenazine (1) · ALPL protein, human (1) · Amino Acids (1) · Amyloid (1) · Antioxidants (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (8) · Shire (4) · Aevi Genomic Medicine, LLC, a Cerecor company (2) · Ironshore Pharmaceuticals and Development, Inc (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · National Institute of Mental Health (NIMH) (2) · Supernus Pharmaceuticals, Inc. (2) · The National Center on Addiction and Substance Abuse at Columbia University (2) · University of Delaware (2) · Vallon Pharmaceuticals, Inc. (2) · Yale University (2) · Alcobra Ltd. (1) · AlkaliDx, Inc. (1) · AstraZeneca (1) · Avekshan LLC (1)
United States (53) · Canada (5) · Israel (5) · Germany (3) · Japan (3) · China (2) · India (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Cuba (1) · Finland (1) · France (1) · Poland (1)
Mary Dozier, Ph.D. (2) · Scott H Kollins, Ph.D. (2) · Aaron T Hogue, Ph.D. (1) · Aaron T Hogue, PhD (1) · Adele Diamond, Ph.D. (1) · Alexander A Ostanin, MD, PhD (1) · Alison E Pritchard, PhD (1) · Andrew W. Heitzer, PhD (1) · Ann Childress, M.D. (1) · Anne B Arnett, PhD (1) · Anne W. Riley, PhD (1) · Anthony Spirito, PhD (1)
PMID 35690720, PMID 37120522, PMID 16930863, PMID 21356232, PMID 23106988, PMID 24297663, PMID 24664093, PMID 25436448, PMID 26397109, PMID 26541307, PMID 26913614, PMID 28639564, PMID 29039979, PMID 29339723, PMID 30196869, PMID 30659782, PMID 31370811, PMID 31677152, PMID 31763491, PMID 32731812, PMID 32781397, PMID 34165190, PMID 34215144, PMID 34303786, PMID 34826114, PMID 35377332, PMID 35770861, PMID 36548042, PMID 37058600, PMID 37385583, PMID 39290059, PMID 40772654, PMID 41776068, PMID 42518155
K24DA023464 (1), R01AT010508 (1), R01DA011755 (1), R01DA033080 (1), R01HD076189 (1), R01MH052135 (1), R01MH063272 (1), R03MH060940 (1), R21DA031305 (1), R21MH067861 (1), R41MH133540 (1), R43MH082461 (1)